TRAUMEEL® PRODUCT MONOGRAPH20

NSAID treatment may have beneficial effects in the early phase of inflammation by preventing prostanoid production, but may also be resolution-toxic, by disrupting the production of anti-inflammatory prostaglandins and lipoxins.[Sugimoto 2016]

Single-target drugs are designed to target a single biological entity (usually a protein) with high selectivity, not taking interactions with other targets into consideration (Figure 3)

Due to network complexity of disease biology, single-target drugs may have unwanted ripple effects on other off-target entities

These ripple effects can potentially cause side effects, limiting the effective dose and effectiveness of the single-target drug

Multitarget drugs can target a larger part of the signaling network (Figure 3) They can balance signaling inhibition with promotion by targeting selected

synergistic pathways The synergistic effect of multiple targets across the signaling network allows the

reduction of pharmacological doses and possible side effects

Traumeel® is a combination of natural ingredients in low concentration, designed to have multiple targets. Therefore, its mode of action is much broader compared to synthetic drugs. With modern technologies, such as single-molecule transcriptome sequencing and bioinformatics, investigating the action on thousands of signaling events simultaneously is possible.

Figure 3 Multitarget drugs provide a better solution for complex processes like inflammation resolution.

COX-2, cyclooxygenase 2; FPR2, formyl peptide receptor 2; LTB4, leukotriene B4; LTAH, leukotriene A4 hydrolase; LXA4, lipoxin A4; PGE2, prostaglandin E2.